The abstract is read at the publisher; the summary is JClub's.
Overall survival in Waldenström macroglobulinemia did not change across diagnosis eras overall (p=0.64), but improved for patients aged <65 years post-2006 (median 18.8 vs 14.1 years, p=0.018).
- Why it matters: Even with expanded therapies, interpreting overall-survival gains is difficult because non-WM deaths can mask or distort progress in WM-specific outcomes.
- What they did: In a single-center retrospective cohort of 1020 patients, investigators compared two diagnosis eras (1996–2005 vs post-2006) using overall survival, cause-specific survival, and competing-risk analysis.
- The result: Cause-specific survival increased from 15.6 years to 18.9 years (p<0.0001), and competing-risk analysis showed reduced WM-related mortality (p<0.001), yet excess mortality persisted with SMR 2.79 (p<0.001) for patients <65 years versus the matched U.S. population.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.